Soc. Generale Discount Zert ATO 2.../ DE000SU1TZS0 /
16/05/2024 10:17:34 | Chg.+0.06 | Bid22:00:43 | Ask22:00:43 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.09EUR | +2.96% | - Bid Size: - |
- Ask Size: - |
Atos SE | - EUR | 28/06/2024 | Call |
GlobeNewswire
16/05
Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats
GlobeNewswire
15/05
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...
GlobeNewswire
13/05
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
29/04
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
15/04
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...
GlobeNewswire
11/04
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
GlobeNewswire
09/04
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...
GlobeNewswire
01/04
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
GlobeNewswire
25/03
Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks
GlobeNewswire
19/03
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...
GlobeNewswire
18/03
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
GlobeNewswire
12/03
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...
GlobeNewswire
06/03
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...
GlobeNewswire
22/02
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
GlobeNewswire
16/01
New report reveals that 94% of global organizations have experienced email security incidents last y...
GlobeNewswire
04/12/2023
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
GlobeNewswire
20/11/2023
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial